Waldenström Macroglobulinemia

Blood Cancers

Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Childhood Cancers

Anal Cancer

Colorectal Cancer

Esophageal Cancer

Gallbladder Cancer

Gastrointestinal stromal tumor

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancers

Bladder Cancer

Kidney Cancer

Prostate Cancer

Testicular Cancer

Genitourinary Cancers

Cervical Cancer

Ovarian Cancer

Uterine Cancer

Vulvar Cancer

Gynecologic Cancer

Head & Neck Cancer

Immunotherapy

Acute Myeloid Leukemia

Leukemia

Mesothelioma

Lung Cancer

Follicular Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin Lymphoma

Small Lymphocytic Lymphoma (SLL)

Lymphoma

Myeloma

Cancer of Unknown Primary

Carcinoid Cancer

Neuroendocrine Cancer

Rare Cancers

Sarcoma

Melanoma

Skin Cancer

Thyroid Cancer

News

Cancer Horizons

All News

Blogs

Caregiving

Diet and Exercise

Financial

Psychosocial

Recipes

Sexual Health

Side Effect

Survivorship

Videos

All Videos

CURE Connections

CURE Expert Connections®

CURE Speaking Out

CURE TV

Educated Patient Sound Bites

On Demand: Webinars

Conferences

Conference Coverage 

Conference Listing 

Events

CURE Adventures

CURE Awards

Educated Patient In Person Education

Educated Patient Virtual Education

Resources

Advocacy Groups

Art Gallery

Clinical Trial Corner

Heal®

Partners

Podcasts

Publications

Share Your Story

Subscribe

The brain cancer condition center is a comprehensive resource for cancer news & oncologist insights on brain cancer. Read more about cancer at CURE.

Brain Cancer | Oncology & Cancer News | Tumor | CURE

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

About Us

Advertise / Support

Editorial Board

Contact Us

CancerNetwork.com

TargetedOnc.com

OncLive.com

OncNursingNews.com

Terms & Conditions

Privacy

Do Not Sell My Information

CURE - Oncology & Cancer News for Patients & Caregivers

Facebook

Youtube

Instagram

Spotlight

Breast Cancer Webinar Series

Cancer Type

Bladder

Breast

Kidney

Lung

Ovarian

Prostate

Skin

About CURE

Press Releases

Write for CURE

1rem

Tumor

CURE’s brain cancer page features the latest cancer news and updates on brain cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in brain cancer.

After a car accident, and experiencing what he thought was a stroke, Matt Newman was diagnosed with brain cancer at the age of 39 — an experience he found strength and courage in.

With a wife and three children at home, as well as a cancer partner in his father-in-law facing his own pancreatic cancer diagnosis, Matt immediately went into fight mode. He utilized fitness and exercise to get through his craniotomy recovery, and went on to write “Starting At The Finish Line,” which tells his personal story.

“I’ve earned my legacy and cancer had nothing to do with it,” he says.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.

Earning Your Legacy: Cancer Has Nothing To Do With It

Ninety percent of patients with cancer enter their first oncology appointment with a nutritional issue; however, Savor Health, who works in conjunctions with Merck’s Your Cancer Game Plan, has set out to combat just that.

 Talks Cancer, founder and CEO of Savor Health, Susan Bratton discussed the importance of nutrition for patients and caregivers before, during and after treatment.

For more information, visit savorhealth.com, and to read some of the organization’s recipes, visit our Spring issue of 

In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.

Addressing Nutritional Needs in Cancer

After receiving a stage 4 neuroblastoma diagnosis at 15 months old, Candace Stevens beat the odds, and has used her experience to shape her career choice today.

Stevens was treated at St. Jude, and now participates in the institution’s LIFE program — research that brings long-term childhood cancer survivors back to St. Jude for regular health screenings throughout their adult lives. The findings from this research are helping survivors learn more about their individual health needs and also providing researchers with novel insights into the late effects of cancer therapy.

In this week’s episode, we spoke with Candace about growing up as a cancer survivor, why programs like St. Jude LIFE are helping other children moving forward, and why everyone should keep believing in miracles.

In this week’s episode of the CURE Talks Cancer podcast, we spoke with a childhood cancer survivor about her journey with stage 4 neuroblastoma, and also about taking part in the St. Jude LIFE research program.

Believing Miracles Can Happen

We’re wrapping up Childhood Cancer Awareness Month by talking to Micah Bernstein, a 7-year-old, three-time survivor of neuroblastoma, and her father, Jeff. 

Micah and Jeff discussed their experiences with the disease, as well as Micah’s participation in clinical trials, being a “tester for the drugs,” as she put it. Now that Micah has no evidence of disease (NED), she hopes that she can inspire other children who face a cancer diagnosis, and one day hopes to become a doctor.

Micah Bernstein is only 7 years old and has already fought cancer three times. Now, she hopes to be an inspiration to other children.

Words of Wisdom from a 7-Year-Old Cancer Survivor

Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.

Larger Tumor Size Linked to Higher Mortality Risk in Brain Cancer

The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse intrinsic pontine glioma.

FDA Grants Breakthrough Status to CAR-T Therapy for Pediatric Brain Tumor 

People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate.

Support Patient Access and Education with the End Brain Cancer Initiative for GiveBIG 2025

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study.

TLX101 Demonstrated Efficacy in Recurrent High-Grade Glioma 

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Clinical Trial to Evaluate Opdivo, Opdualag in Glioblastoma

Following the results of a hypothesis-generating study of immunotherapy in glioblastoma, a type of brain cancer, a phase 2 clinical trial is set to evaluate Opdivo (nivolumab) with or without relatlimab, a combination known as Opdualag, among patients with isocitrate dehydrogenase (IDH)-wildtype newly diagnosed glioblastoma (ndGBM).

The GIANT trial, set to be held in the United States at Duke University in Durham, North Carolina, was designed by professor Georgina Long, following up on her research into glioblastoma that was published in 

Long is the medical director of Melanoma Institute Australia (MIA), and chair of melanoma medical oncology and translational research at MIA and Royal North Shore Hospital, The University of Sydney. 

 article looked at the case of one patient with IDH-wild-type, MGMT promoter unmethylated glioblastoma who received treatment with a single dose of triplet immunotherapy followed by surgery who, after 17 months, showed no definitive sign of recurrence.

“It really showed that despite what the oncology field thinks about glioblastoma, that the immune system is not able to be activated against it, you can actually do that in certain circumstances,” said Long. “So when I came up with the idea and the hypothesis, because I developed drugs in melanoma — yes, we are curing over 50% of patients with immune stimulants or immunotherapy, [but] we still have 45% of patients who die from melanoma, and they die quickly — from my experience in the translational lab and in the clinic, because I'm a medical oncologist and translational researcher, my thinking about those sort of patients and the resistance to immunotherapy is what I applied to the glioblastoma.”

In light of the findings, the GIANT trial has an estimated start date of June 1, 2025, and will enroll approximately 92 patients, according to its listing on clinicaltrials.gov.

Long discussed her findings and the upcoming GIANT trial in an interview with CURE.

So the principles are, first of all, choose the right immunotherapies. You need to use CTLA4. That's very important as part of your regimen in these terrible, terrible tumors. Number two, use it early. Immunotherapy is best if you're going to test it. Test it early. Number three, that publication, was hypothesis generating, we don't want to give false hope. We now need to show clinical benefit in a trial, and we are opening that. And in fact, I designed that within six weeks, and got the drugs within 10 weeks of that diagnosis of that patient. And then number four, the science showed activation of T cells, T cells infiltrating the glioblastoma after treatment and drug bound to the T cells. They're the four principles from that piece of work that I led, and now the trial should open in 2025 across America and Australia. It's an Australian trial driven by the Australians, but the Americans came on board, and now it's co led by Duke University and the [Walter and Eliza Hall Institute of Medical Research] and [Peter MacCallum Cancer Centre] in Australia, but that came from the work I did and I put together.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education,

don’t forget to subscribe to CURE®’s newsletters here.

Maggie Bushway reflected on her memoir “Pearls: A Memoir on Childhood Cancer and Hope,” and her journey of healing and resilience after brain cancer.

Brain Cancer Survivor Reflects on Memoir and Her Journey

In 2003, 7-year-old Maggie Bushway started writing a book about her experience with brain cancer, while her father, Rob, began documenting their family’s story on a blog. Two decades later, Maggie, now 28, came across a box containing her dad’s printed blog posts and fragments of her unfinished book. With years of reflection on her health, family and hope, she felt ready to bring the pieces together and complete the story she began as a child.

, Maggie Bushway reflected on rediscovering her childhood writings and her father's blog posts that recorded her early experience with brain cancer. She discussed the emotional process of integrating these pieces into her book, “Pearls: A Memoir on Childhood Cancer and Hope.”

Bushway shared how her family brought comfort during treatment and emphasized the importance of finding joy in small moments, such as building forts with her siblings or creating fashion show skits.

She also discussed how the writing process was exposed. However, her memoir became a form of therapeutic healing that helped her through the journey while facing new challenges.

I was given so many prognoses that showed that [I] wasn't going to be able to graduate high school, wasn't going to be able to go to college, live on my own and have a career. And I just want kids to know that you know your prognosis isn't your life. You can try to accomplish your dreams. You can push to make things happen. And just because the doctor said that you can't do something, it doesn't mean that you'll never be able to do it with treatment and healing and different kinds of therapy. In the case of brain cancer, you can find a way to make it happen.

For more news on cancer updates, research and education, don’t forget to 

subscribe to CURE®’s newsletters here.

Maggie Bushway, a brain cancer survivor, revisited her childhood writings and her father's blog documenting her cancer journey. Now 28, she completed her memoir, "Pearls: A Memoir on Childhood Cancer and Hope," reflecting on her experiences and the support from her family. The writing process served as therapeutic healing, helping her navigate new challenges. Bushway emphasizes that a prognosis does not define one's life, encouraging others to pursue their dreams despite medical predictions. Her story highlights resilience, hope, and the power of family support.

SurVaxM, which is being study in gliobastoma, targets a certain protein that is found on the brain cancer cells. 

An Expert Breakdown of SurVaxM, the Novel Brain Cancer Vaccine

A novel cancer vaccine, SurVaxM, is being studied for the treatment of patients with newly diagnosed glioblastoma. A trial of the drug is currently fully enrolled, and results can be expected around this time next year, according to Dr. Manmeet S. Ahluwalia.

Ahluwalia is the chief scientific officer and chief of medical oncology and deputy director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute. He recently sat down with CURE® at the 2024 

American Society of Clinical Oncology Annual Meeting

FDA Grants Fast Track Designation to SurVaxM for Newly Diagnosed Glioblastoma

Ahluwalia explained that SurVaxM targets the survivin protein, which is found on gliobastoma cells and is associated with poor outcomes.

“Essentially, if survivin is expressed, patients with glioblastoma have worse outcomes. So, the intent of this vaccine is to not only reverse that negative prognostic factor but on top, build efficacy [in treating the disease],” Ahluwalia said.

SurVaxM is a peptide-based vaccine that targets survivin. Survivin is a peptide which is presented the cancer cells and is not present in the normal cells. We have found survivin expression in almost all of the glioblastoma patients. It is an intracellular (located inside of a cell) protein, but it is expressed on the surface and that's why we are utilizing this peptide-based vaccine to target survivin. Survivin is an anti-apoptotic pathway (meaning a protein that inhibits cancer cell death). Essentially, if survivin is expressed, patients with glioblastoma have worse outcomes. So, the intent of this vaccine is to not only reverse that negative prognostic factor but on top, build efficacy [in treating the disease].

SurVaxM, which is being studied in gliobastoma, targets a certain protein that is found on the brain cancer cells. 

Conference

In an interim analysis of a phase 2 study of Ibrance (palbociclib) researchers found the drug had a cranial benefit for patients with brain metastasis that harbored a cyclin-dependent kinases (CDK) pathway alteration, according to data presented at the 2019 Society for NeuroOncology Annual Meeting.

Ibrance is a CDK inhibitor that has shown positive results for HR-positive and HER2-negative breast cancer, but now shows promise for tackling brain metastasis that present this CDK pathway. In a genomically-guided trial, eight of the first 14 patients showed inter cranial benefit from the drug, according to Dr. Brastianos Priscilla.

Priscilla, director of the central nervous system metastasis program at Massachusetts General Hospital in Boston, had the chance to sit down with 

 and discuss the results of the phase 2 trial and what she believes this means for the future of Ibrance and treating patients with brain metastases.   

This study design was a Simon Two-Stage design where we were to enroll 15 patients to start, and if at least two patients had clinical benefit intracranially than we would proceed to the second stage of a Simon Two-Stage design. And then finally, at 30 patients, if at least six patients out of the 30 had a clinical benefit intracranially, then the treatment would be considered worthy of further study.

With the interim analysis, we were able to review the first 14 invaluable cases, and of those patients, eight patients had a clinical benefit intracranially. Which means that number one, palbociclib shows promise in this patient population of patients with brain metastases harboring CDK pathway alterations. And number two, that running a gnomically guided brain metastases trial is feasible.

New findings show that Ibrance has the potential to help patients with brain metastases that harbor a CDK pathway alteration.

Ibrance Shows Promise in Patients with Brain Metastases Who Harbor a CDK Pathway Alteration

Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities at 

Hear firsthand from an Optune user and caregiver, like Steve.

Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities.

Optune User Journey: Meet Steve

Olympic figure skater Scott Hamilton discusses the benefits of proton therapy.

Unlike traditional radiation, where there may be some “pass through,” proton therapy leaves little to no collateral damage by affecting tissue that is not being treated. Hamilton, who survived testicular cancer and a brain tumor, is optimistic about the future of cancer care, including immunotherapy, targeted therapy and proton therapy. In fact, after his brain tumor recurred, he asked his doctor about proton therapy and was told, “It’s an elegant option.”

One of Scott Hamilton's doctors told him that proton therapy was, "an elegant choice."

Scott Hamilton Talks Proton Therapy

The Biden Cancer Summit in Washington, DC, brought together patients, survivors, caregivers, advocates and special guests for one central purpose: make progress in the fight against cancer.

The event kicked off with a special performance by Evan Ruggiero, an osteosarcoma survivor who had his leg amputated at the age of 19. However, Ruggiero did not let the surgery stop him from pursuing his passion of dance.

Former Vice President Joe Biden also spoke to the crowd about how his and his wife's lives were changed after their son, Beau, was diagnosed with glioblastoma five years ago. Beau ended up passing away from the disease in 2015 at age 46. Watching their son go through cancer has inspired the Bidens to join in the fight against the disease, ultimately leading to the Biden Cancer Initiative -- something Mr. and Mrs. Biden are now known for around the globe.

Read more about the Biden Cancer Summit: 

https://www.curetoday.com/articles/turning-cancer-fear-into-cancer-fierce

CURE headed out to Washington, DC to cover the Biden Cancer Summit.

Brain Cancer

Latest News